Vascular Closure Device in Transcatheter Aortic Valve Replacement
Plug-based Percutaneous Vascular Closure Device in Transcatheter Aortic Valve Replacement
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden
- Department of Cardiology, Karolinska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients undergoing transfemoral TAVI at the Karolinska University Hospital
Exclusion Criteria:
- Patients undergoing TAVI with access other than transfemoral
- Use of closure device other than MANTA
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients undergoing transfemoral TAVI with MANTA closure
Patients undergoing transfemoral transcatheter aortic valve replacement with femoral access site closure using the novel plug-based vascular closure device (MANTA, Teleflex/Essential Medical Inc., Malvern, Pennsylvania, USA).
|
Femoral access site closure using the MANTA closure device
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with major vascular complications
Time Frame: 6 week follow up
|
Major vascular access site complications according to the VARC-2 definitions
|
6 week follow up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with minor vascular complications
Time Frame: 6 week follow up
|
Minor vascular access site complications according to the VARC-2 definitions
|
6 week follow up
|
|
Number of patients with vascular closure device failure
Time Frame: 6 week follow up
|
Percutaneous vascular closure device failure according to the VARC-2 definitions
|
6 week follow up
|
|
Number of patients with life-threatening, disabling or major bleeding
Time Frame: 6 week follow up
|
Life-threatening, disabling or major bleeding complications according to the BARC definitions
|
6 week follow up
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MANTA TAVI
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.